BUY Aurobindo Pharma — Arun Kumar Mantri
byArun Kumar MantriHorizon: NA (inferred Intraday)2 Sept 2026, 9:34 am ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
NewsEt-Markets·31 Aug · yesterday
3 advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · adjacent horizon·1 Sept · yesterday
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.
NSE · Press Release·31 Aug · 2d ago
Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in
BSE · Company Update·31 Aug · 2d ago
Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.
BSE · Company Update·1 Sept · yesterday
Aurobindo Pharma’s API plant gets three US FDA observations after inspection
NewsCnbc-Tv18·28 Aug · 4d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.